Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06163534 · ClinicalTrials.gov registry record
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
A clinical trial of Head and Neck Squamous Cell Carcinoma, sponsored by Tempus AI.
- Recruiting
- Registry status
- 500
- Enrollment target
- 20
- Study locations
NCT06163534: Recruiting study of Head and Neck Squamous Cell Carcinoma, sponsored by Tempus AI.
NCT06163534 is a study of Head and Neck Squamous Cell Carcinoma that is actively recruiting participants, run by Tempus AI. The registered enrollment target is 500 participants, above the 113-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (342% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06163534, a study of Head and Neck Squamous Cell Carcinoma, is actively recruiting participants, sponsored by Tempus AI.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Primary Outcome
Use NGS, ctNDA assessments, RNA analysis, and other multiomic testing to uncover biomarkers of collected blood and tissue samples that may predict outcomes, identify markers related to disease, identify markers related to mechanism of drug action, and inform future research.
Conditions Studied
Study Locations (20)
California
- City of Hope - Duarte
- USC/Norris Comprehensive Cancer Center - Los Angeles
- University of California, Los Angeles - Los Angeles
- Stanford - Palo Alto
- Providence Medical Foundation - Santa Rosa
Georgia
- Morehouse - Atlanta
- Piedmont Healthcare - Atlanta
- Winship Cancer Institute, Emory University - Atlanta
Illinois
- Northwestern University Feinberg School of Medicine - Chicago
- Cancer Care Specialists of Illinois - Decatur
- Illinois Cancer Care - Peoria
Missouri
- Oncology Hematology Associates - Springfield
- Washington University in St. Louis - St Louis
Kansas
- University of Kansas - Westwood
Maryland
- University of Maryland - Baltimore
Massachusetts
- Dana Farber Cancer Institute - Boston
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-08-01 |
| Est. Completion | 2028-03-01 |
What NCT06163534 shows while recruiting
NCT06163534 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 124 other Head and Neck Squamous Cell Carcinoma trials with a reported enrollment target (342% higher).
The record links to 1 condition, with Head and Neck Squamous Cell Carcinoma appearing as the primary indexed condition, and to 0 interventions.
NCT06163534 names 20 study sites across 11 states, led by California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06163534 about?
NCT06163534 is a clinical study titled "A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)". The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
What is the current status of trial NCT06163534?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-08-01. Estimated completion is 2028-03-01.
What conditions does trial NCT06163534 study?
This clinical trial studies the following conditions: Head and Neck Squamous Cell Carcinoma.
Who is sponsoring clinical trial NCT06163534?
This trial is sponsored by Tempus AI, which has 13 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06163534 being conducted?
This trial has 20 study locations across California, Georgia, Illinois, Kansas, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Head and Neck Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06163534's enrollment target sits among peer trials
500 6th of 124 higher than 117 of 124 other Head and Neck Squamous Cell Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Head and Neck Squamous Cell Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
3D Specimen Maps for RT Planning
RECRUITING
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Dosing Study of Radiation Combined With Tislelizumab and Pamiparib in Patients With Previously Treated Head and Neck Cancer
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase II Study of Neoadjuvant Cetuximab and Cemiplimab in Patients Undergoing Surgery for HNSCC
RECRUITING · Phase 2
-
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI